South Carolina Department of Health and Human Services

Post Office Box 8206 Columbia, South Carolina 29202-8206 www.scdhhs.gov

January 2, 2009

MEDICAID BULLETIN

DENTISTS
HOME HEALTH
HOSPITALS
MEDICAL CLINICS
MENTAL HEALTH AND
REHABILITATION CLINICS
PHARMACY
PHYSICIANS

TO: Providers Indicated

SUBJECTS: I. South Carolina Medicaid Preferred Drug List

II. Hepatitis C Care Coordination ProgramIII. Web Based Prior Authorization (WebPA)

I. South Carolina Medicaid Preferred Drug List

The Preferred Drug List (PDL) has been revised to include several additional therapeutic classes. Attached to this bulletin is a comprehensive listing of products within all therapeutic classes that comprise the PDL. Upon initial implementation of the specified PDL changes, pharmacists will observe soft edits when pharmacy claims are submitted for products that will eventually require prior authorization (PA). This period of soft editing will occur until February 25, 2009. The soft edit will not cause the claim to reject; however, pharmacists are asked to take this opportunity to inform both the prescriber and beneficiary of the eventual PA requirement.

Effective with dates of service February 25, 2009, hard edits will be activated (*i.e.*, pharmacy claims without PA approval will deny) for newly designated non-preferred products within the therapeutic classes listed below. The **complete PDL** (attached to this bulletin) includes the following changes:

Additional PDL DRUG CLASSES		
1) Immunosuppressants		
2) Androgenic Agents		
3) Adrogen Hormone Inhibitors		
4) NK1 Antagonist		
5) Hepatitis B Therapy		
6) Long Acting Beta Adrenergic Nebulizers		
7) Ophthalmic Macrolide		
8) Nitroimidazoles		
9) NMDA Receptor Antagonist		

NEW PDL CLASSES			
PREFERRED	NON-PREFERRED		
Immunosuppressants			
AZASAN® AZATHIOPRINE CELLCEPT® CYCLOSPORINE GENGRAF® IMURAN® MYFORTIC® NEORAL® PROGRAF® RAPAMUNE® SANDIMMUNE®			
Androgenic Agents			
Androderm® Androgel® Testim®			
Androgen Hormone Inhibitors			
Avodart® Finasteride	Proscar®		
NK1 Antagonist			
Emend®			
Hepatitis B Therapy BARACLUDE® EPIVIR HBV® HEPSERA® TYZEKA®			
Long Acting Beta Atonist Nebulizers			
	BROVANA® PERFOROMIST®		
Ophthalmic Macrolide			
	AZASITE®		
NITROIMIDAZOLES			
METRONIDAZOLE	FLAGYL® FLAGYL ER® TINDAMAX®		
NMDA Receptor Antagonist			
NAMENDA			

CHANGES TO EXISTING PDL CLASSES				
PREFERRED	NON-PREFERRED			
Cholinesterase Inhibitors				
	Aricept ODT®	Removed from PDL		

Prescribers are strongly encouraged to write prescriptions for "preferred" products. However, if a prescriber deems that the patient's clinical status necessitates therapy with a PA-required drug, the prescriber (or his/her designated office personnel) is responsible for initiating the PA request. A prospective, approved PA request will prevent rejection of prescription claims at the pharmacy due to the PA requirement.

All PA requests should be telephoned or submitted by fax to the First Health Clinical Call Center by the prescriber or the prescriber's designated office personnel. The toll-free telephone and fax numbers for the Clinical Call Center are 866-247-1181 and 888-603-7696, respectively. The First Health Clinical Call Center telephone number is reserved for use by healthcare professionals and should not be furnished directly to beneficiaries. [First Health's South Carolina Medicaid beneficiary call center telephone number for Pharmacy Services is 800-834-2680. Providers may furnish the beneficiary call center telephone number to Medicaid beneficiaries for Pharmacy Services-related issues only.] Providers are reminded that questions about Medicare eligibility issues and Part D drug plans should be directed to 1-800-MEDICARE.

A pharmacy claim submitted for a PA-required product that has not been approved for Medicaid reimbursement will reject. If this occurs, the pharmacist should contact the prescriber so that a determination may be made regarding whether a drug *not* requiring a PA is clinically appropriate for the patient.

II. Hepatitis C Care Coordination Program

To improve patient compliance and clinical outcomes, South Carolina Medicaid will be implementing a specialty care management program for beneficiaries receiving certain specialty medications. The major focus of this program is to provide outreach to a smaller population of South Carolina Medicaid beneficiaries who will receive high intensity intervention services to improve their care and outcomes. This program, administered by First Health Services Corporation, assists beneficiaries in an attempt to avoid duplication of existing services and serves as a "safety net" to identify any problems that may have occurred during the first level of services.

With this initiative, beneficiaries are identified by the approval of a PA for a Hepatitis C treatment agent. Once enrolled in the program, beneficiaries will be contacted and educated on any medical or non-medical issues related to their disease or drug therapy, monitored for potential adverse reactions, reminded of refills to insure compliance with their drug therapy regime and assisted with transportation issues if necessary.

Medicaid Bulletin January 2, 2009 Page 4

Prescribers will be contacted in order to assist in monitoring any laboratory results where dose adjustment of medication is warranted and to communicate any concerns revealed in the beneficiary outreach conversations (in compliance with HIPAA requirements). Pharmacy providers will also be contacted in order to coordinate refills and ensure medications are stored appropriately.

The first class of drugs to be included in this program will be the Hepatitis C agents. Effective February 1, 2009, these agents will require a PA. Once the PA has been approved, the First Health Services Call Center representative will ask for beneficiary contact information from the physician. Calls to the beneficiary will begin the day following the approval of the PA.

New medication classes will be added to this program in the near future. South Carolina Medicaid anticipates this additional layer of patient interaction will benefit all involved in the care of these beneficiaries.

III. Web Based Prior Authorization (WebPA)

South Carolina Medicaid is pleased to announce the availability of an additional method of requesting a PA for pharmacy services. In the near future, prescribers or their designated staff members will be able to request a PA via a web-enabled process. This option will be available twenty-four hours a day, seven days a week and three hundred sixty five days a year. More information regarding this process may be found at http://southcarolina.fhsc.com. WebPA should be available to South Carolina Medicaid prescribers by March 1, 2009.

Questions regarding this bulletin should be directed to the Department of Pharmacy Services at (803) 898-2876.

/s/

Emma Forkner Director

EF/mga

Attachments

NOTE: To sign up for Electronic Funds Transfer of your Medicaid payment, please go to: http://www.dhhs.state.sc.us/dhhsnew/hipaa/index.asp and select "Electronic Funds Transfer (EFT)" for instructions.



{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

ANALGESIC

NSAIDs

Diclofenac Potassium Diclofenac Sodium

Diflunisal

Etodolac

Fenoprofen

Flurbiprofen

Ibuprofen

Indomethacin

Indomethacin SR

Ketoprofen

Ketoprofen ER

Ketorolac

Meclofenamate Sod.

Nabumetone

Naproxen

Naproxen Sodium

Oxaprozin

Piroxicam

Sulindac

Tolmetin Sodium

NSAIDs, RECEPTOR SELECTIVE*

Celebrex® Meloxicam

* Class level PA is in effect for this class. Once criteria are met, the agents listed on the PDL are preferred.

OPIOIDS, EXTENDED RELEASE

Duragesic® Patch Kadian® Morphine Sulfate ER*

ANTI-INFECTIVE

ANTIBACTERIALS

CEPHALOSPORINS, 2ND GENERATION

Cefprozil Cefuroxime

CEPHALOSPORINS, 3RD GENERATION

Cefdinir (all dosage forms)
Spectracef® Tablets

MACROLIDES/KETOLIDES

Azithromycin
Clarithromycin
Clarithromycin XL
EryPed®
Ery-Tab®
Erythromycin Base
Erythromycin Estolate
Erythromycin Ethylsuc.
Erythromycin Stearate
Erythrocin Stearate
Erythromycin & Sulfisox.

QUINOLONES, 2ND AND 3RD GENERATION

Avelox® Ciprofloxacin Ofloxacin

*Prescribers are encouraged to ensure compliance with FDA approved indications.

ANTIFUNGALS, ORAL

ONYCHOMYCOSIS AGENTS

Gris-Peg® Griseofulvin Terbinafine

ANTIPROTOZOALS, ORAL

NITROIMIDAZOLES

Metronidazole

ANTIVIRALS, ORAL

HERPES ANTIVIRALS

Acyclovir Famciclovir Valtrex®

CARDIOVASCULAR

ACE INHIBITORS (ACEI)

Benazepril
Benazepril/HCTZ
Captopril
Enalapril
Enalapril/HCTZ
Lisinopril
Lisinopril/HCTZ

ACEI, CCB COMBINATIONS

Lotrel® Tarka®

ANGIOTENSIN RECEPTOR BLOCKERS (ARB)

Avalide®
Avapro®
Benicar®
Benicar HCT®
Cozaar®
Diovan®
Diovan HCT®
Hyzaar®
Micardis®
Micardis HCT®
Teveten®
Teveten HCT®

BETA BLOCKERS

Acebutolol
Atenolol
Atenolol/Chlorthalidone
Betaxolol
Bisoprolol Fumarate
Bisoprolol/HCTZ
Carvedilol
Labetolol
Metoprolol Tartrate
Nadolol
Pindolol
Propranolol
Propranolol/HCTZ
Sotalol
Timolol

CALCIUM CHANNEL BLOCKERS (CCB), DIHYDROPYRIDINES

Amlodipine
Dynacirc CR®
Felodipine
Isradipine
Nicardipine
Nifedical XL®
Nifedipine ER and SA

CALCIUM CHANNEL BLOCKERS (CCB), NON-DIHYDROPYRIDINES

Cartia XT®
Diltia XT®
Diltiazem
Diltiazem ER and XR
Taztia XT®
Verapamil
Verapamil ER
Verapamil SR

CCB/ARB COMBINATION PRODUCTS

Exforge®

DIRECT RENIN INHIBITORS

Tekturna®∗

* Prior authorization is required if an ARB has not been prescribed previously for the patient.

DIRECT RENIN INHIBITOR/DIURETICS

Tekturna HCT®*

* Prior authorization is required if an ARB has not been prescribed previously for the patient.

ENDOTHELIN RECEPTOR ANTAGONISTS

Tracleer®*

*Patients currently established on non-preferred therapy will be grandfathered.



{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

LIPOTROPICS

BILE ACID SEQUESTERING RESINS

Cholestyramine
Cholestyramine Light
Colestipol
Welchol®

FIBRIC ACID DERIVATIVES

Gemfibrozil Lofibra® Tricor®

NIACIN DERIVATIVES

Niaspan®

NIACIN/STATIN COMBINATIONS

Advicor® Simcor®

STATINS

Altoprev® Crestor® Lescol ® Lescol XL® Lipitor® Lovastatin Pravastatin Simvastatin Vytorin®

CHOLESTEROL-ABSORPTION INHIBITORS Zetici®

CENTRAL NERVOUS SYSTEM

ALZHEIMER'S AGENTS

CHOLINESTERASE INHIBITORS

Aricept® tablets Exelon® (Capsules and Solution) Galantamine

NMDA RECEPTOR ANTAGONIST

Namenda®

ANTI-CONVULSANT AGENTS

CARBAMAZEPINE DERIVATIVES

Carbamazepine (all dosage forms)
Carbatrol®
Epitol®
Tegretol XR®
Trileptal® (tablets and suspension)

FIRST GENERATION ANTICONVULSANTS

Celontin®
Depakote ER®
Depakote Sprinkles®
Ethosuximide
Felbatol®
Mebaral®
Phenytoin
Phenytoin Sodium ER
Primidone
Valproic Acid

* Prior authorization is not required for Dilantin® if"Brand Medically Necessary" criteria are met

SECOND GENERATION ANTICONVULSANTS

Gabapentin Keppra® Lamictal® Lyrica® Topamax® Zonisamide

ANTI-MIGRAINE AGENTS

SELECTIVE SEROTONIN AGONISTS*

Imitrex® Tablets Imitrex® Injection Imitrex® Nasal Spray Treximet®

* See the listing at: http://southcarolina.fhsc.com for the quantity limits for this class. (Click on Providers, then Documents, then Pharmacy Quantity Limits.)

ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS

Amphetamine Salt Combination Dexmethylphenidate Immediate Release Dextroamphetamine Dextroamphetamine SR Metadate ER® Methylin® Methylin ER® Methylphenidate Methylphenidate SR Ritalin LA®* Adderall XR®* Concerta®* Focalin XR®* Vyvanse®*

* Generic agents considered "first-line" when appropriate.

MULTIPLE SCLEROSIS AGENTS

Avonex®
Avonex Administration
Pack®
Betaseron®
Copaxone®
Rebif®

PARKINSON'S AGENTS

NON-ERGOT DOPAMINE RECEPTOR AGONISTS

Ropinirole

SEDATIVE/HYPNOTICS, NON-BARBITURATES

Temazepam Zolpidem

ENDOCRINE AND METABOLIC

ANTI-DIABETICS

ALPHA-GLUCOSIDASE INHIBITORS

Glyset® Precose®

AMYLIN ANALOGS*

Symlin®

* Prior authorization is required if patient is not currently receiving insulin therapy.

BIGUANIDES

Metformin Metformin ER

BIGUANIDE COMBINATION AGENTS

ActoPlus Met® Avandamet®

DPP-4 INHIBITORS AND COMBINATIONS*

Janumet® Januvia®

* Prior authorization is required if metformin, a thiazolidinedione or a sulfonylurea has not been prescribed previously for the patient.



{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

INCRELIN MIMETICS*

Bvetta®

* Prior authorization is required if metformin, a thiazolidinedione or a sulfonylurea product has not been prescribed previously for the patient.

NSULINS

Lantus® Vial Levemir® Vial Novolin® N Novolin® R Novolin® 70/30 Novolog® Novolog® Mix 70/30 Humalog® 50/50

MEGLITINIDES

Starlix®

SULFONYLUREAS, SECOND GENERATION

Glimepiride Glipizide Glipizide ER Glyburide Glyburide Micronized

THIAZOLIDINEDIONES

Actos® Avandia®

THIAZOLIDINEDIONE SULFONYLUREA COMBINATIONS*

Avandaryl® Duetact®

* Prior authorization is required if a single agent thiazolidinedione or sulfonylurea product has not been prescribed previously for the patient.

ELECTROLYTE DEPLETERS

Fosrenol® Phoslo® Renagel®

BIPHOSPHONATES OSTEOPOROSIS

Alendronate

GROWTH HORMONE

Genotropin® Norditropin® Saizen®

* Class level PA is in effect for this class. Once criteria are met, the agents listed on the PDL are preferred.

GASTROINTESTINAL

ANTI-EMETICS (ORAL)

NK1 ANTAGONISTS

Emend®

SEROTONIN RECEPTOR ANTAGONISTS

Granisetron Ondansetron

* See the listing at: http://southcarolina.fhsc.com for the quantity limits for this class. (Click on Providers, then Documents, then Pharmacy Quantity Limits.)

HISTAMINE-2 RECEPTOR ANTAGONISTS

Famotidine Ranitidine

PROTON INHIBITORS*

Nexium® Capsules Prevacid®

PUMP

Omeprazole OTC

* Class level PA is in effect for this class. Once criteria are met, the agents listed on the PDL are preferred.

ULCERATIVE COLITIS

THERAPY

Asacol®
Balsalazide Disodium
Canasa® Rectal Supp.
Mesalamine Enema
Pentasa®
Sulfasalazine

GENITOURINARY

ALPHA BLOCKERS FOR BPH

Flomax®
Uroxatral®

ANTISPASMODICS

Detrol LA® Enablex® Oxybutynin Oxytrol ® Sanctura® VESIcare®

HEMATOLOGICAL AGENTS

ANTICOAGULANTS – LOW MOLECULAR WEIGHT HEPARINS

Arixtra® Fragmin® Lovenox®

HEMATOPOIETIC AGENTS

Aranesp® Procrit®

PLATELET INHIBITORS

Aggrenox® Plavix®

HORMONE RELATED THERAPY

ANDROGENIC AGENTS

Androderm® Adrogel® Testim®

ANDROGEN HORMONE INHIBITOR

Avodart® Finasteride

IMMUNOLOGICS

IMMUNOMODULATORS, INJECTABLE

Enbrel® Humira®

IMMUNOMODULATORS, TOPICAL

Elidel® *
Protopic® *

* Prescribers: Please use these agents as advised by the respective manufacturer and reserve for only those patients who have failed traditional eczema therapy.

IMMUNOMODULATORS, ORAL AND INJECTABLE

HEPATITIS B THERAPY

Baraclude® Epivir® Hepsera® Tyzeka®

*Vriead® is unaffected by the PDL and is available without Prior Authorization.

HEPATITIS C THERAPY, PEGYLATED INTERFERONS

Pegasys® & Conv. Pack Peg-Intron® & Redipen

HEPATITIS C THERAPY, RIBAVIRINS

Rebetol® Ribavirin 200mg tablets



{Non-listed products belonging to therapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

IMMUNOSUPPRESSANTS

Azasan®
Azathioprene
Cellcept®
Cyclosporine
Gengraf®
Imuran®
Myfortic®
Neoral®
Prograf®
Rapamune®

OPHTHALMICS

Sandimmune®

ANTIHISTAMINES, OPHTHALMIC

Pataday® Patanol® Elestat®

GLAUCOMA THERAPY

ALPHA-2 ADRENERGICS

Brimonidine Tartrate Alphagan P®

BETA BLOCKERS

Betaxolol HCI Carteolol HCI Levobunolol HCI Metipranolol Timolol Maleate

CARBONIC ANHYDRASE INHIBITORS

Azopt® Cosopt® Trusopt®

PROSTAGLANDIN AGONISTS

Lumigan® Travatan® Travatan Z® Xalatan®

QUINOLONES MACROLIDES, OPHTHALMIC

&

2nd

AND

Ciprofloxacin HCI Vigamox® Zymar®

OTICS

QUINOLONES, OTIC

Ciprodex® Ofloxacin Otic Drops

RESPIRATORY

ANTI-CHOLINERGICS

Atrovent® HFA Combivent® Spiriva®

ANTIHISTAMINES, GENERATION DECONGESTANT COMBINATIONS

Loratadine-D OTC Loratadine-D OTC Zyrtec® OTC or RX Zyrtec D® OTC or RX

BETA ADRENERGIC DEVICES, SHORT-ACTING INHALERS

Albuterol CFC Ventolin® HFA Xopenex® HFA

BETA ADRENERGIC DEVICES, LONG-ACTING METERED DOSE INHALERS

Serevent Diskus®*

* Prescribers are reminded of the warnings associated with the use of long acting beta agonists.

BETA ADRENERGIC AGENTS, SHORT-ACTING NEBULIZERS

*Both agents in this class require Prior Authorization.

BETA ADRENERGIC AGENTS, SHORT-ACTING NEBULIZERS

Albuterol Metaproterenol Xopenex®*

* Generic agents should be considered as "firstline" therapy when appropriate.

GLUCOCORTICOIDS

INHALATION DEVICES

Asmanex® Azmacort® Flovent Diskus® Flovent HFA® Qvar®

INTRANASAL STEROIDS

Fluticasone propionate Nasonex®

GLUCOCORTICOIDS AND LONG-ACTING BETA-2 ADRENERGICS

Advair® Diskus Advair® HFA

* Prescribers are reminded of the warnings associated with the use of long acting beta agonists

LEUKOTRIENE RECEPTOR ANTAGONISTS

Accolate® Singulair®

TOPICAL AGENTS FOR ACNE

BENZOYL PEROXIDE/CINDAMYCIN COMBOS

Benzaclin® Duac® & CS

TOPICAL RETINOIDS

Retin-A Micro® (excludes Pump)
Tretinoin

TOPICAL AGENTS FOR PSORIASIS

TOPICAL AGENTS FOR PSORIASIS

Dovonex® Psoriatec®

TOPICAL ANTIBIOTICS

TOPICAL ANTIBOTICS

Mupirocin Ointment Altabax®* Bactroban®* Cream

* Generic agents should be considered "first line" therapy when appropriate.



South Carolina Department of Health and Human Services Preferred Drug List Products Within PDL Therapeutic Classes Are Available Without Prior Authorization (PA)

{Non-listed products belonging to the rapeutic classes that comprise the PDL require PA} {Note that ALL the rapeutic classes are not included on the PDL.}

Listing Updated: December 2008

Δ

ACCOLATE ACEBUTOLOL

ACTOS

ACTOPLUS MET ACYCLOVIR ADDERALL XR ADVAIR DISKUS ADVAIR HFA

ADVICOR ALBUTEROL CFC

ALBUTEROL NEBULIZER

ALPHAGAN P ALTOPREV ALTABAX AMLODIPINE

AMPHETAMINE SALT COMBINATION

ARANESP ARICEPT ARIXTRA ASACOL ASMANEX ATENOLOL

ATENOLOL/CHLORTHALIDONE

ATROVENT HFA

AVALIDE
AVANDAMET
AVANDARYL
AVANDIA
AVAPRO
AVELOX
AVINZA

AZITHROMYCIN AZMACORT AZOPT В

BACTROBAN CREAM
BALSALAZIDE DISODIUM

BENAZEPRIL

BENAZEPRIL/HCTZ

BENICAR
BENICAR HCT
BENZACLIN
BETASERON
BETAXOLOL

BETAXOLOL HCL OPHTHALMIC
BISOPROLOL FUMARATE

BISOPROLOL/HCTZ

BRIMONIDINE TARTRATE OPHTH.

BYETTA

C

CANASA RECTAL SUPPOSITORIES

CAPTOPRIL

CARBAMAZEPINE (ALL

FORMULATIONS)
CARBATROL

CARTEOLOL HCL OPHTHALMIC

CARTIA XT
CARVEDILOL
CEFDINIR
CEFPROZIL
CEFUROXIME
CELEBREX
CELONTIN

CHOLESTYRAMINE LIGHT CLARITHROMYCN CLARITHROMYCIN XL CIPRODEX OTIC CIPROFLOXACIN

CHOLESTYRAMINE

CIPROFLOXACIN HCL OPHTHALMIC

COLESTIPOL
COMBIVENT
CONCERTA
COPAXONE
COSOPT

COZAAR CRESTOR D

DEPAKOTE
DEPAKOTE ER
DEPAKOTE SPINKLE

DETROL LA

DEXMETHYLPHENIDATE IR DEXTROAMPHETAMINE DEXTROAMPHETAMINE SR DICLOFENAC POTASSIUM DICLOFENAC SODIUM

DIFLUNISAL
DILTIA XT
DILTIAZEM
DILTIAZEM ER
DILTIAZEM XR
DIOVAN
DIOVAN HCT
DOVONEX
DUETACT

DURAGESIC PATCH DYNACIRC CR

Ε

ELESTAT OPHTHALMIC

ELIDEL
ENABLEX
ENALAPRIL
ENALAPRIL/HCTZ

ENBREL EPITOL EPOGEN ERYPED ERY-TAB

ERYTHROCIN STEARATE ERYTHROMYCIN BASE ERYTHROMYCIN ESTOLATE

ERYTHROMYCIN ETHYLSUCCINATE

ERYTHROMYCIN STEARATE

ERYTHROMYCIN WITH SULFISOXAZOLE

ETHOSUXIMIDE ETODOLAC

EXELON CAPSULES AND SOLUTION

EXFORGE



{Non-listed products belonging to therapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

FACTIVE

FAMOTIDINE

FAMVIR

FELBATOL

FELODIPINE FENOPROFEN

FLOMAX

FLOVENT DISKUS

FLOVENT HFA

FLURBIPROFEN

FLUTICASONE

FOCALIN XR

FOSAMAX

FOSRENOL

FRAGMIN

G

GABAPENTIN

GEMFIBROZIL

GENOTROPIN

GLIMEPIRIDE

GLIPIZIDE

GLIPIZIDE ER

GLYBURIDE

GLYBURIDE MICRONIZED

GLYSET

GRANISETRON

GRISEOFULVIN

GRIS-PEG

Н

HUMALOG 50/50

HUMIRA

HYZAAR

IBUPROFEN

IMITREX INJECTION

IMITREX NASAL SPRAY

IMITREX TABLETS

INDOMETHACIN

INDOMETHACIN SR

ISRADIPINE

Л

JANUMET

AIVUNAL

K

KADIAN

KEPPRA

KETOPROFEN

KETOPROFEN ER

KETOROLAC

L

LABETOLOL

LAMICTAL

I AMOTRIGINE

LANTUS VIAL

LESCOL

LESCOL XL

LEVAQUIN

LEVEMIR VIAL

LEVOBUNOLOL HCL OPHTHALMIC

LIPITOR

LISINOPRIL

LISINOPRIL/HCTZ

LOFIBRA

LORATADINE OTC (ALL FORMS)

LORATADINE-D OTC

LOTREL

LOVASTATIN

LOVENOX

LUMIGAN

LUNESTA

LOINESTA

LYRICA

MESALAMINE ENEMA

MESYLAMINE

METADATE ER

METAPROTERENOL NEBULIZER

METFORMIN

METFORMIN ER

METHYLIN

METHYLIN ER

METHYLPHENIDATE

METHYLPHENIDATE SR

METIPRANOLOL OPHTHALMIC

METOPROLOL TARTRATE

MICARDIS

MICARDIS HCT

MORPHINE SULFATE ER

MUPIROCIN OINTMENT

N

NABUMETONE

NADOLOL

NAPROXEN

NAPROXEN SODIUM

NASACORT AQ

NASONEX

NEXIUM CAPSULES

NIASPAN

NICARDIPINE

NIFEDICAL XL

NIFEDIPINE ER

NIFEDIPINE SA

NORDITROPIN

NOVOLIN 70/30

NOVOLIN N

NOVOLIN R

NOVOLOG MIX 70/30

MEBARAL

M

MECLOFENAMATE SODIUM

MELOXICAM

First Health Clinical Call Center Telephone: 866-247-1181 (toll-free)

Fax: 888-603-7696 (toll-free)

0

ONDANSETRON OFLOXACIN

OFLOXACIN OTIC DROPS

OMEPRAZOLE OTC

OXAPROZIN



{Non-listed products belonging to therapeutic classes that comprise the PDL require PA} {Note that ALL therapeutic classes are not included on the PDL.}

December, 2008

OXYBUTININ OXYTROL

P

PATADAY OPHTHALMIC PATANOL OPHTHALMIC

PEGASYS

PEGASYS CONVENIENCE PACK

PEG-INTRON

PEG-INTRON REDIPEN

PENTASA PHENYTOIN

PHENYTOIN SODIUM ER

PHOSLO

PINDOLOL PIROXICAM

PRAVASTATIN

PRECOSE

PREVACID

PROCRIT

PRIMIDONE

PROPRANOLOL

PROPRANOLOL/HCTZ

PROTOPIC PSORIATEC

RANITIDINE

RAZADYNE

REBETOL

RENAGEL

REQUIP DOSE PACK

REQUIP

REBIF

Q

QVAR

RETIN-A MICRO

RIBAVIRIN TABLETS

RITALIN LA

S

SAIZEN SANCTURA

SEREVENT DISKUS

SIMCOR

SIMVASTATIN

SINGULAIR

SOTALOL

SPECTRACEF TABLETS

SPIRIVA

STARLIX

SULINDAC

SULFASALAZINE

SYMLIN

TIMOLOL

TIMOLOL MALEATE GEL-FORMING

TIMOLOL MALEATE OPHTHALMIC

TOLMETIN SODIUM

TOPAMAX

TRAVATAN

TRACLEER

TRETINOIN

TREXIMET TRILEPTAL

TRICOR

TRUSOPT

U

UROXATRAL

V

VALPROIC ACID

VALTREX

VENTOLIN HFA

VERAPAMIL

VERAPAMIL ER

VERAPAMIL SR

VIGAMOX OPHTHALMIC

VESICARE

VYTORIN

VYVANSE

W

WELCHOL

X

XALATAN

XOPENEX

XOPENEX HFA

Y

TARKA

T

TAZTIA XT

TEGRETOL XR

TEKTURNA

TEKTURNA HCT

TEMAZEPAM

TERBINAFINE

TEVETEN

TEVETEN HCT

First Health Clinical Call Center Telephone: 866-247-1181 (toll-free) Fax: 888-603-7696 (toll-free) Z

ZETIA

ZOLPIDEM

ZONISAMIDE

ZYMAR OPHTHALMIC

ZYRTEC (ALL FORMULATIONS)

ZYRTEC D